NDA 207027 · Novartis
Promacta Kit
Eltrombopag Olamine · Oral
Priority reviewOrphanLast checked: Nov 20, 2026Latest source record: Jun 6, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2015
Aug 24, 2015
Approved uses
1
Original approval plus efficacy supplements
Registered trials
22
5 Phase 3, 0 recruiting
FAERS reports
19,469
11,673 serious, 4,302 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: RISK FOR HEPATIC DECOMPENSATION IN PATIENTS WITH CHRONIC HEPATITIS C and RISK OF HEPATOTOXICITY In patients with chronic hepatitis C, PROMACTA in combination with interferon and ribavirin may increase the risk of hepatic decompensation [see Warnings and Precautions (5.1)] . PROMACTA may increase the risk of severe and potentially life-threatening hepatotoxicity. Monitor hepatic function and discontinue dosing as recommended [see Warnings and Precautions (5.2)] . WARNING: RISK FOR HEPATIC DECOMPENSATION IN PATIENTS WITH CHRONIC HEPATITIS C and RISK OF HEPATOTOXICITY See full prescribing information for complete boxed warning. In patients with chronic hepatitis C, PROMACTA in combination with interferon and ribavirin may increase the risk of hepatic decompensation. ( 5.1 ) PROMACTA may increase the risk of severe and potentially life-threatening hepatotoxicity. Monitor hepatic...
What it is approved for
From the label in effect Dec 18, 2025.
PROMACTA is a thrombopoietin receptor agonist indicated: for the treatment of thrombocytopenia in adult and pediatric patients 1 year and older with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. PROMACTA should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increase the risk for bleeding. ( 1.1 ) for the treatment of thrombocytopenia in patients with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy. PROMACTA should be used only in patients with chronic hepatitis C whose degree of thrombocytopenia prevents the initiation of interferon-based therapy or limits the ability to maintain interferon-based therapy. ( 1.2 ) in combination with standard immunosuppressive therapy for the first-line treatment of adult and pediatric patients 2 years and older with severe aplastic anemia. ( 1.3 ) for the treatment of patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy. ( 1.3 ) Limitations of Use: PROMACTA is not indicated for the treatment of patients with myelodysplastic syndrome (MDS). ( 1.4 ) Safety and efficacy have not been established in combination with direct-acting antiviral agents used without interferon for treatment of chronic hepatitis C infection. ( 1.4 ) 1.1 Treatment of Thrombocytopenia in Patients With Persistent or Chronic Immune Thrombocytopenia PROMACTA is indicated for the treatment of thrombocytopenia in adult and pediatric patients 1 year and older with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. PROMACTA should be used only in patients...
Mechanism: Eltrombopag is a TPO-receptor agonist that interacts with the transmembrane domain of the human TPO-receptor (also known as cMpl) and initiates signaling cascades that induce proliferation and differentiation of megakaryocytes leading to increased platelet production.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 24, 2015 Original approval · Type 3 - New Dosage Form and Type 4 - New Combination · priority review OrphanLabelReviewPediatric Medical Review
2 products under this application
- PROMACTA KIT · ELTROMBOPAG OLAMINE EQ 25MG ACID/PACKET · FOR SUSPENSION, ORAL · Prescription · TE AB
- PROMACTA KIT · ELTROMBOPAG OLAMINE EQ 12.5MG ACID/PACKET · FOR SUSPENSION, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Eltrombopag Olamine" as an intervention, any sponsor and status, largest first.
- EXTEND (Eltrombopag Extended Dosing Study)Pivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT00351468 · 302 participants · Start Jun 2006 · Primary completion Jul 2015
Drug: eltrombopag olamine (SB-497115-GR) · For: Purpura, Thrombocytopaenic, Idiopathic
Sites: Huntsville, Alabama; Mobile, Alabama; Jonesboro, Arkansas · 110 sites in all
- RAISE: Randomized Placebo-Controlled Idiopathic Thrombocytopenic Purpura (ITP) Study With EltrombopagPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT00370331 · 197 participants · Start Nov 2006 · Primary completion Jul 2008
Drug: eltrombopag; Placebo · For: Purpura, Thrombocytopaenic, Idiopathic
Sites: Duarte, California; Los Angeles, California; San Francisco, California · 115 sites in all
GlaxoSmithKlineGSK (GSK)
NCT01098487 · 167 participants · Start May 2010 · Primary completion May 2014
Drug: Eltrombopag olamine · For: Purpura, Thrombocytopaenic, Idiopathic
Sites: New York, New York; Hradec Králové, Czechia; Olomouc, Czechia · 34 sites in all
- A Randomized Trial Comparing Optimized rhTPO Treatment With Eltrombopag Treatment in Pre-treated ITP PtsPivotal-lookingCompleted
Institute of Hematology & Blood Diseases Hospital, ChinaAcademic, hospital or other
NCT05583838 · 157 participants · Start Nov 22, 2022 · Primary completion Feb 28, 2024
Drug: rhTPO; Eltrombopag · For: Previously Treated Primary Immune Thrombocytopenia
Sites: Nanning, China; Shijiazhuang, China; Tangshan, China · 17 sites in all
- Sequential rhTPO and Eltrombopag Following Glucocorticoids for Severe Adult ITPPivotal-lookingNot yet recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyAcademic, hospital or other
NCT07189910 · 150 participants (planned) · Start Dec 1, 2025 · Primary completion Nov 1, 2027
Drug: Eltrombopag · For: Primary Immune Thrombocytopenia (ITP)
Sites: Wuhan, China
- Safety and Efficacy Study for Solid Tumor Patients Treated With EltrombopagPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT01147809 · 130 participants · Start Jun 2010 · Primary completion Jan 2015
Drug: Eltrombopag olamine · For: Thrombocytopaenia
Sites: Sedona, Arizona; Hot Springs, Arkansas; Rancho Cucamonga, California · 86 sites in all
GlaxoSmithKlineGSK (GSK)
NCT00903422 · 98 participants · Start May 14, 2009 · Primary completion Jun 26, 2012
Drug: eltrombopag olamine · For: Myelodysplastic Syndrome
Sites: Birmingham, Alabama; Santa Monica, California; Stanford, California · 65 sites in all
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT01830660 · 96 participants (planned) · Start Apr 2012 · Primary completion Jun 2013
Drug: Hetrombopag Olamine Tablets; placebo · For: Healthy
Sites: Chengdu, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- platelet count decreased3,722
- death3,223
- drug ineffective1,482
- platelet count increased1,069
- fatigue1,054
- headache884
- nausea756
- diarrhoea738
- malaise567
- off label use525
- product use in unapproved indication513
- asthenia485
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2009 | 118 |
| 2010 | 414 |
| 2011 | 674 |
| 2012 | 316 |
| 2013 | 348 |
| 2014 | 513 |
| 2015 | 1,142 |
| 2016 | 707 |
| 2017 | 979 |
| 2018 | 1,126 |
| 2019 | 1,590 |
| 2020 | 1,736 |
| 2021 | 2,198 |
| 2022 | 2,750 |
| 2023 | 2,407 |
| 2024 | 1,235 |
| 2025 | 802 |
| 2026 | 414 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Bioequivalence and Food Effect Assessment of Eltrombopag Olamine Tablets in Healthy Chinese Subjects: An Open, Randomized, Single-Dose, and Two-Period Crossover Study.
Wang J, Zhao Z, Tao Y, et al. · Clin Pharmacol Drug Dev 2024 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- A Single-Center, Randomized, Open-Label, Two-Formulation, Two-Sequence, Two-Period Crossover Study to Evaluate the Bioequivalence of Two Eltrombopag Olamine Tablets (25 mg) in Healthy Chinese Subjects in the Fed State.
Wu K, Ren Q, Wang Y, et al. · Clin Drug Investig 2026 · Randomized Controlled Trial
Sponsor: Novartis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.